Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...
Mineralys TherapeuticsMLYS stock nearly doubled Tuesday after AstraZenecaAZN, on Saturday, published promising results for its experimental hypertension treatment. Over the course of 12 weeks, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results